Take an individualised approach when treating frail, elderly patients with nocturia
AbstractNocturia is a complex symptom that is attributed to a wide range of causes, including advanced age, comorbidities and medications. Non-pharmacological treatments are first-line options in the management of nocturia in frail, elderly patients due to their safety in this vulnerable population. If pharmacotherapy is required, the benefits must be carefully weighed against the potential for adverse effects. Desmopressin, α-antagonists, antimuscarinic drugs and β3‑adrenergic agonists have been identified as potential pharmacological options, though the evidence for their use in frail, elderly patients is limited. (S...
Source: Drugs and Therapy Perspectives - July 22, 2021 Category: Drugs & Pharmacology Source Type: research
Correction to: Guselkumab in psoriatic arthritis: a profile of its use
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - July 9, 2021 Category: Drugs & Pharmacology Source Type: research
Integrase strand transfer inhibitors can simplify HIV treatment
AbstractIntegrase strand transfer inhibitors (INSTIs) bictegravir, dolutegravir, cabotegravir, elvitegravir and raltegravir, mostly available as fixed dose combinations are recommended treatments in both newly diagnosed and treatment-experienced patients with HIV. Their efficacy, good tolerability and simplified dosing regimens facilitate treatment adherence and a recently approved cabotegravir 4-weekly injection is a major advance. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - June 30, 2021 Category: Drugs & Pharmacology Source Type: research
Acute cough remedies for children: so many options, not enough evidence
AbstractAcute cough is a common complaint in children and adolescents, with cough remedies commonly self-prescribed by parents/caregivers to manage typically self-limiting illnesses. Drugs that affect mucociliary factors or target the cough reflex have equivocal evidence of efficacy, while non-drug natural compounds such as honey have moderate quality evidence for efficacy and tolerability. Nevertheless, cough remedies continue to be used despite limited data in the paediatric population; further clinical trials are required for the various options currently available. Acute cough management should also include standardize...
Source: Drugs and Therapy Perspectives - June 28, 2021 Category: Drugs & Pharmacology Source Type: research
A systematic review of clinical pharmacy services in pediatric inpatients
ConclusionThis work provides a basis for harmonizing the deployment of pediatric CPS in hospital to improve patient safety. Because pharmacists ’ time resources are limited, CPS should be prioritized according to hospital population, service organization, and needs evaluation. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - June 15, 2021 Category: Drugs & Pharmacology Source Type: research
Bulevirtide in chronic hepatitis D: a profile of its use
AbstractBulevirtide (HEPCLUDEX®), a first-in-class entry inhibitor, is a new option for the treatment of chronic hepatitis D, caused by hepatitis delta virus (HDV) infection, in HDV-RNA positive adults with compensated liver disease. In a pivotal phase IIb trial in patients with chronic hepatitis D, treatment with bulevirtide in combination with tenofovir significantly reduced HDV RNA levels compared with treatment of the underlying HBV infection with tenofovir alone. Alanine aminotransferase (ALT) levels were also normalised by bulevirtide combination therapy. Bulevirtide is generally well tolerated; the most common adve...
Source: Drugs and Therapy Perspectives - June 14, 2021 Category: Drugs & Pharmacology Source Type: research
The effect of educational interventions on medication dispensing errors: a randomised controlled trial in community pharmacies in Jordan
ConclusionEducational interventions decreased the incidence of errors and reduced the clinical severity of incidents during dispensing. However, the effects of this approach on the system-induced errors (e.g. errors due to work overload and drug supply shortages) are limited. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - June 11, 2021 Category: Drugs & Pharmacology Source Type: research
Drug poisoning in nursing homes: a retrospective study of data from the Danish Poison Information Centre
ConclusionAlthough it is not known to what extent potential poisonings are reported to the DPIC, the data can be used to describe reasons behind medication errors and potential poisonings that occur in nursing homes and thus contribute to the work of preventing medication errors. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - June 11, 2021 Category: Drugs & Pharmacology Source Type: research
Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States
Conclusions There remains a knowledge gap with regard to biosimilars, and lack of consensus on how the naming convention is and should be utilized in clinical practice. The data also suggest that effective biosimilar education could aid in promoting familiarity with the naming convention among health care pro viders. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - June 8, 2021 Category: Drugs & Pharmacology Source Type: research
Guselkumab in psoriatic arthritis: a profile of its use
AbstractGuselkumab (TREMFYA®), a fully human immunoglobulin G1 λ (IgG1λ) monoclonal antibody that selectively targets interleukin (IL)-23, is an effective and generally well-tolerated treatment option for active psoriatic arthritis. Guselkumab is administered subcutaneously and can be used alone or in combination with methotrexate. In randomized, double-blind , placebo-controlled phase 3 trials in adults with active psoriatic arthritis and an inadequate response to or intolerance of standard treatment, guselkumab was effective in reducing disease activity and structural damage progression. Guselkumab conferred improveme...
Source: Drugs and Therapy Perspectives - June 3, 2021 Category: Drugs & Pharmacology Source Type: research
Asenapine transdermal delivery system (Secuado ®) in schizophrenia: a profile of its use in the USA
AbstractAsenapine, an atypical antipsychotic indicated for the treatment of schizophrenia, was first available as a twice-daily sublingual tablet. However, there are some challenges associated with the use of sublingual asenapine. More recently, a comparable transdermal formulation of asenapine (Secuado®) has been approved in the USA as the first antipsychotic patch for the treatment of schizophrenia in adults. Asenapine transdermal delivery system (TDS) offers a simpler and more convenient dosage regimen and avoids adverse events related to sublingual administration, potentially leading to better adherence to treatment. ...
Source: Drugs and Therapy Perspectives - June 1, 2021 Category: Drugs & Pharmacology Source Type: research
Systemic muscular weakness after botulinum toxin A administration: a review of the literature
ConclusionBased on data from the identified cases of systemic muscle weakness with botulinum toxin A, this adverse event was more common in female, younger, patients with spasticity or neurogenic detrusor overactivity indication or those receiving abobotulinum toxin A formulation and/or higher botulinum toxin A doses. A prevention strategy may include reducing the dose of botulinum toxin A to those recommended by the US FDA. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - May 31, 2021 Category: Drugs & Pharmacology Source Type: research
Eosinophilic oesophagitis in children responds well to corticosteroids, PPIs and diet
AbstractEosinophilic oesophagitis is a chronic inflammatory syndrome that is the leading cause of paediatric dysphagia in Western countries. Diagnosis requires upper gastrointestinal endoscopy and biopsies. Treatment aims to reduce inflammation, alleviate symptoms and prevent long-term oesophageal fibrosis and strictures. First-line therapies in children include proton pump inhibitors, swallowed topical corticosteroids and elimination diets. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - May 12, 2021 Category: Drugs & Pharmacology Source Type: research
Agents for the treatment of fatty liver disease: focus on essential phospholipids
AbstractNonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed countries, with a prevalence that is increasing. In addition to being a disease of the liver, NAFLD is associated with an increased risk of type 2 diabetes mellitus, chronic kidney disease, and cardiovascular disease, with the latter being the most common cause of death in patients with NAFLD. A large number of agents have been trialed in patients with NAFLD or nonalcoholic steatohepatitis (NASH), with or without comorbidities. However, no pharmacologic agents are yet specifically licensed for the treatment of NAFLD. Curr...
Source: Drugs and Therapy Perspectives - May 10, 2021 Category: Drugs & Pharmacology Source Type: research
COVID-19 vaccination in pregnancy
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - May 6, 2021 Category: Drugs & Pharmacology Source Type: research
